SSG
RVMD icon

Summit Securities Group’s Revolution Medicines RVMD Stock Holding History

Summit Securities Group’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.9K Buy
+400
New +$40.4K ﹤0.01% 429
2025
Q3 		– Sell
-3,822
Closed -$141K – 1306
2025
Q2 		$141K Buy
+3,822
New +$147K 0.03% 306
2024
Q1 		– Sell
-24,500
Closed -$703K – 832
2023
Q4 		$703K Buy
+24,500
New +$589K 0.06% 163

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Summit Securities Group's RVMD Position: Q1 2026 in Review

Summit Securities Group opened a new position in Revolution Medicines (RVMD) in Q1 2026: 400 shares worth $38.9K. The stake represents ﹤0.01% of the portfolio and ranks #429 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in RVMD as recently as Q2 2025.

Summit Securities Group first reported a position in RVMD in Q4 2023 and has held it in 3 quarters since. The position peaked at $703K in Q4 2023. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Summit Securities Group held 400 shares of Revolution Medicines worth $38.9K as of Q1 2026.
  • Revolution Medicines was a new Summit Securities Group position in Q1 2026.
  • Revolution Medicines made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #429 holding.
  • Summit Securities Group first reported a position in Revolution Medicines in Q4 2023 and has held it in 3 quarters since.
  • Summit Securities Group's Revolution Medicines position peaked at $703K in Q4 2023.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.